BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR+, HER2- advanced breast cancer.
Bent Ejlertsen
Research Funding - Amgen; Novartis
Other Remuneration - Novartis
Guy Heinrich Maria Jerusalem
Consultant or Advisory Role - Novartis
Sara A. Hurvitz
Research Funding - Novartis; Roche
Other Remuneration - Novartis; Roche
Richard H. De Boer
Consultant or Advisory Role - Novartis; Roche
Tanya Taran
Employment or Leadership Position - Novartis
Tarek Sahmoud
Employment or Leadership Position - Novartis
Howard A. Burris
No relevant relationships to disclose